Tag Archives: Anthony Vendetti

BioPharmX Corp (BPMX) Receives a Buy from Maxim Group

Maxim Group analyst Anthony Vendetti maintained a Buy rating on BioPharmX Corp (BPMX – Research Report) today and set a price target of $0.40. The company’s shares opened today at $0.13. Vendetti wrote: “On March 14, 2019, BPMX reported a

Maxim Group Keeps Their Buy Rating on Celsius Holdings Inc (CELH)

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Celsius Holdings Inc (CELH – Research Report) today and set a price target of $8. The company’s shares opened today at $3.88. Vendetti commented: “Market open, CELH reported better-than-expected 4Q18

Maxim Group Keeps a Sell Rating on National Beverage (FIZZ)

In a report released today, Anthony Vendetti from Maxim Group maintained a Sell rating on National Beverage (FIZZ – Research Report), with a price target of $45. The company’s shares closed yesterday at $68.27, close to its 52-week low of

Maxim Group Believes Joint Corp (NASDAQ: JYNT) Won’t Stop Here

In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on Joint Corp (JYNT – Research Report), with a price target of $18. The company’s shares closed yesterday at $12.02, close to its 52-week high of

Analysts Offer Insights on Healthcare Companies: Ellex Medical Lasers Limited (Other OTC: ELXMF) and Genomic Health (NASDAQ: GHDX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ellex Medical Lasers Limited (ELXMF – Research Report) and Genomic Health (GHDX – Research Report). Ellex Medical Lasers Limited (ELXMF) Maxim Group analyst Anthony Vendetti

Maxim Group Sticks to Its Buy Rating for Reed’s Inc (REED)

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Reed’s Inc (REED – Research Report) today and set a price target of $4. The company’s shares opened today at $2.35. Vendetti said: “Market close, REED reported lower-than-expected preliminary 4Q18